☆ 4.7 Article

Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Microbiology

Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program

Michael J. Satlin et al.

Summary: Cefiderocol is a potential treatment option for infections caused by multidrug-resistant Pseudomonas aeruginosa, especially for isolates with limited or no alternative therapies. However, its effectiveness for isolates with higher MIC values (>1 μg/mL) remains uncertain.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

添加到收藏夹

Article Immunology

Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial

Richard R. Watkins et al.

Summary: There is an urgent need for novel antibiotics to combat antimicrobial resistance, particularly against difficult to treat gram-negative pathogens like Acinetobacter baumannii-calcoaceticus complex (ABC). Pathogen-targeted development programs offer an innovative approach to address this issue. An example of such development is the beta-lactam/beta-lactamase inhibitor combination antibiotic SUL-DUR, which specifically targets drug-resistant ABC. The successful clinical trial, ATTACK, demonstrated the effectiveness and safety of SUL-DUR in treating carbapenem-resistant ABC infections, highlighting the potential of pathogen-targeted development programs in addressing antimicrobial resistance.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Infectious Diseases

Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms

Monirul I. Sajib et al.

Summary: Cefiderocol is shown to be possibly associated with lower all-cause mortality than previously thought. The use of dual antibiotics in conjunction with cefiderocol may be advantageous in reducing mortality compared to using cefiderocol alone.

ANTIBIOTICS-BASEL (2023)

添加到收藏夹

Article Infectious Diseases

Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study

Gabriele Palermo et al.

Summary: This study aimed to evaluate the effectiveness of cefiderocol in a real-life setting for treating carbapenem-resistant gram-negative bacteria infections. The results showed that cefiderocol had a clinical cure rate of 56.1% and a microbiological eradication rate of 56.1% in patients with these infections. Septic shock was identified as an independent factor associated with mortality.

ANTIBIOTICS-BASEL (2023)

添加到收藏夹

Article Infectious Diseases

Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: a propensity-weighted cohort study

Emanuele Rando et al.

Summary: This study examined the association between cefiderocol-containing regimens and 28-day mortality in CRAB-VAP patients. Results showed that cefiderocol-containing regimens were associated with reduced 28-day mortality. However, the small sample size and observational design limit the conclusions of the study. Future RCTs are needed to establish the definite role of cefiderocol in these infections.

JAC-ANTIMICROBIAL RESISTANCE (2023)

添加到收藏夹

Article Microbiology

New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae

Dennis Nurjadi et al.

Summary: This study found that the emergence of resistance to Cefiderocol in metallo-beta-lactamase-producing bacteria is facilitated by mutations in the CirA siderophore receptor, which are induced by the New Delhi metallo-beta-lactamase. However, inhibiting the metallo-beta-lactamase activity using dipicolinic acid can successfully prevent the development of Cefiderocol-resistant mutants. Therefore, caution should be taken when using Cefiderocol to treat infections caused by metallo-beta-lactamase-producing bacteria.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Immunology

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections

Pranita D. Tamma et al.

Summary: The Infectious Diseases Society of America (IDSA) has provided updated guidance on the treatment of antimicrobial-resistant infections, focusing on treating AmpC-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. The guidance is based on clinical experience, expert opinion, and a review of available literature, as published data on optimal treatment options are limited. This document emphasizes treatment approaches for infections in the United States, considering differences in resistance epidemiology and the availability of specific anti-infectives internationally.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Infectious Diseases

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

Mical Paul et al.

Summary: These guidelines address the targeted antibiotic treatment of 3GCephRE and carbapenem-resistant Gram-negative bacteria, focusing on the effectiveness of individual antibiotics and on combination versus monotherapy. Most recommendations are based on low-certainty evidence.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update

Emily N. Drwiega et al.

Summary: The review summarizes studies on drug penetration into pulmonary epithelial lining fluid, focusing on comparisons of plasma and ELF concentrations of antibacterial agents in healthy adult subjects and critically ill patients. The significance of changes in intrapulmonary penetration and the need for further studies relating ELF concentrations to clinical response are highlighted. Studies are warranted to evaluate the relationship between intrapulmonary penetration and clinical and microbiological outcomes in critically ill patients with lower respiratory tract infections.

CLINICAL PHARMACOKINETICS (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects

Nao Kawaguchi et al.

Summary: A study developed an intrapulmonary pharmacokinetic (PK) model of Cefiderocol and assessed its PK profile in lungs. The results showed that the lung penetration ratio of Cefiderocol was higher in patients with pneumonia compared to healthy subjects, and the ELF exposure in most patients with nosocomial pneumonia exceeded the minimum inhibitory concentration for a significant amount of time. Adequate dosing regimens were found to achieve the desired therapeutic outcomes in critically ill patients with pneumonia.

JOURNAL OF CLINICAL PHARMACOLOGY (2022)

添加到收藏夹

Article Microbiology

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

Marco Falcone et al.

Summary: Cefiderocol appears to be a promising therapeutic option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, with a potential protective effect on 30-day mortality. However, further studies are needed to address the issue of microbiological failure.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Review Infectious Diseases

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance

Stamatis Karakonstantis et al.

Summary: Cefiderocol is a promising drug that can overcome most beta-lactam resistance mechanisms. Resistance is uncommon but alarming proportions have been reported in recent cohorts. Various mechanisms, especially the coexpression of multiple beta-lactamases, contribute to resistance. Heteroresistance is prevalent in Acinetobacter baumannii, but its clinical impact is still uncertain.

ANTIBIOTICS-BASEL (2022)

添加到收藏夹

Article Infectious Diseases

Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022

Marco Coppi et al.

Summary: This study reports a nosocomial outbreak caused by a cefiderocol-resistant NDM-1-producing Klebsiella pneumoniae (NDM-Kp) strain in a large tertiary care hospital in Florence, Italy. The outbreak was sustained by clonal expansion of a mutant with an inactivated cirA gene, which exhibited high-level resistance to FDC independently of exposure to the antibiotic.

EUROSURVEILLANCE (2022)

添加到收藏夹

Article Public, Environmental & Occupational Health

Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?

Silvia Corcione et al.

Summary: This study evaluated the characteristics and outcomes of patients with Gram-negative infections treated with cefiderocol in combination or monotherapy. The results showed no significant differences in clinical outcomes between combination therapy and monotherapy. Further research is needed to determine if combination therapy with cefiderocol can provide advantages in the prognosis of critically ill patients.

JOURNAL OF INFECTION AND PUBLIC HEALTH (2022)

添加到收藏夹

Review Microbiology

Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?

Patricia J. Simner et al.

Summary: Cefiderocol is a novel siderophore-conjugated cephalosporin that shows activity against multidrug-resistant Gram-negative bacilli. It utilizes a siderophore component to bind iron and enter bacterial cells, leading to cell death. Further clinical studies are needed to determine its effectiveness against other organisms.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

添加到收藏夹

Article Immunology

Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients

Marco Falcone et al.

Summary: In this study, cefiderocol was used to treat patients with bacteremia or ventilator-associated pneumonia caused by drug-resistant strains, showing a 70% clinical success rate and 90% survival rate. However, two patients experienced microbiological failure, highlighting the need for future prospective studies to further evaluate the effectiveness of the treatment.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti et al.

Summary: The study assessed the efficacy and safety of cefiderocol versus best available therapy in the treatment of patients with carbapenem-resistant Gram-negative infections. Cefiderocol showed similar clinical and microbiological efficacy to best available therapy in this heterogeneous patient population with infections caused by carbapenem-resistant Gram-negative bacteria, suggesting it as an option for the treatment of carbapenem-resistant infections in patients with limited treatment options.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Richard G. Wunderink et al.

Summary: Cefiderocol was found to be non-inferior to high-dose, extended-infusion meropenem in terms of all-cause mortality on day 14 in patients with Gram-negative nosocomial pneumonia, with similar tolerability. This suggests that cefiderocol is a potential option for the treatment of patients with nosocomial pneumonia, including those caused by multidrug-resistant Gram-negative bacteria.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Microbiology

Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study

Alexandre Bleibtreu et al.

Summary: Cefiderocol, a novel siderophore cephalosporin, has shown in vitro activity against carbapenem-resistant Gram-negative pathogens and stability towards all carbapenemases. This study in France aimed to describe the first cases of compassionate use of cefiderocol and its efficacy, revealing a need for caution in using orphan drugs during this period; mainly targeting respiratory tract infections.

MICROORGANISMS (2021)

添加到收藏夹

Article Infectious Diseases

Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens

Jacob E Choby et al.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections

Marianna Meschiari et al.

Summary: This study describes the real-life experience of using cefiderocol in XDR and difficult-to-treat resistant Pseudomonas aeruginosa infections without other treatment options available. Clinical cure and microbiological cure rates were 70.6% and 76.5% respectively, with a mortality rate of 35.3%.

JAC-ANTIMICROBIAL RESISTANCE (2021)

添加到收藏夹

Article Infectious Diseases

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study

Renato Pascale et al.

Summary: This study confirms the potential role of cefiderocol in the treatment of CR-Ab infection, but larger clinical studies are needed for further validation.

JAC-ANTIMICROBIAL RESISTANCE (2021)

添加到收藏夹

Article Infectious Diseases

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study

Renato Pascale et al.

Summary: This study analyzed the impact of cefiderocol use on patients with severe COVID-19 admitted to the ICU and further diagnosed with carbapenem-resistant Acinetobacter baumannii (CR-Ab) infection. The results suggest that cefiderocol may have a potential role in the treatment of CR-Ab infection, but larger clinical studies are needed for confirmation.

JAC-ANTIMICROBIAL RESISTANCE (2021)

添加到收藏夹

Review Infectious Diseases

Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms

Pranita D. Tamma et al.

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2019)

添加到收藏夹

Article Infectious Diseases

Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects

Takayuki Katsube et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)

添加到收藏夹

Article Infectious Diseases

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

Simon Portsmouth et al.

LANCET INFECTIOUS DISEASES (2018)

添加到收藏夹

Article Microbiology

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria

Akinobu Ito et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)

添加到收藏夹

Article Medicine, General & Internal

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

添加到收藏夹

Article Medicine, General & Internal

Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline

Paul E. Stevens et al.

ANNALS OF INTERNAL MEDICINE (2013)

添加到收藏夹

Article Medicine, General & Internal

Validation of a modified Early Warning Score in medical admissions

CP Subbe et al.

QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.